Better BP lowering with combination therapy of telmisartan and amlodipine than amlodipine alone PDF (508KB): Telmisartan and amlodipine combination Recent data show that treatment with Twynsta – a single-pill combination of telmisartan, an angiotensin receptor blocker (ARB), and amlodipine, a calcium channel blocker (CCB) – results in significant reductions in blood pressure (BP) in patients with […]
Interactions with Angiotensin II receptor antagonists
February 1, 2011 by Leave a Comment
Concomitant use not recommended Potassium sparing diuretics or potassium supplements Angiotensin II receptor antagonists attenuate diuretic induced potassium loss. K+ sparing diuretics including spirinolactone, eplerenone, triamterene, or amiloride, K+ supplements, or K+-containing salt substitutes may increase serum K+ levels significantly. If concomitant use is indicated because of documented hypokalaemia, the products should be administrated with […]
Champix (varenicline)
February 1, 2011 by Leave a Comment
Champix is a medicinal product authorised for use throughout the European Union since December 2006 through the European licensing process for the treatment of smoking cessation in adults. It contains varenicline, a non-nicotine aid which acts as a partial agonist at the nicotinic α4β2 receptor and so can help reduce the cravings and withdrawal symptoms […]
CVD: A Global Epidemic
February 1, 2011 by Leave a Comment
Cardiovascular diseases kill more people each year than any others. In 2004, 7.2 million people died of coronary heart disease, 5.7 million from stroke or another form of cerebrovascular disease (WHO statistics). The 4 top causes of death (World Health Organisation, 2004 figures) CBD: Cerebrovascular Diseases; CHD: Coronary Heart Diseases; LRTI: Lower Respiratory Tract […]
Highlights from the ESC 2010 Congress
February 1, 2011 by Leave a Comment
The importance of lifestyle changes in the management of CVD Highlights form the European Society of Cardiology (ESC) Congress 20101 held in Stockholm, Sweden, included a session focusing on the opportunities for improvement of the CVD global epidemic. Modifiable causes of coronary heart disease Most of the causes of coronary heart disease (CHD) are related […]
Highlights from the ESC 2010 Congress
February 1, 2011 by Leave a Comment
The Future of Hypertension Guidelines Highlights form the European Society of Cardiology (ESC) Congress 20101 held in Stockholm, Sweden, included a session focusing on hypertension guidelines. Current barriers to guideline implementation and potential solutions were presented. Clinical guidelines on the management of cardiovascular risk factors including hypertension are numerous. While they share common themes, such […]
Allopurinol Teva
February 1, 2011 by Leave a Comment
Company: Teva Pharmaceuticals Ireland. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Allopurinol 100mg, 300mg. Description: White, round biconvex tablets, debossed 4K1 (100mg) or 2K1 (300mg) on one side, plain on the other. Presentations: 100mg-100, €4.55; 300mg-100, €10.60. Indications: Adults: All forms of hyperuricaemia not controllable by diet including secondary hyperuricaemia of differing origin and […]
Anastrozole Teva
February 1, 2011 by Leave a Comment
Company: Teva Pharmaceuticals Ireland. Legal category: Prescription. GMS. Sport prohibited. Active ingredient: Anastrozole 1mg. Description: White to off‑white, film‑coated round‑shaped tablet, debossed with 93 on one side and A10 on the other. Presentation: 28, €64.14. Indication: Treatment of advanced breast cancer in postmenopausal women. Pharmacology: Anastrozole is a potent and highly selective non‑steroidal aromatase inhibitor. […]
Ixiaro
February 1, 2011 by Leave a Comment
Company: Novartis Vaccines and Diagnostics (distributed by Allphar Services Ltd). Legal category: Sport permitted. Active ingredient: Inactivated Japanese encephalitis virus strain SA14-14-2, 6μg/0.5ml (corresponding to a potency of ≤ 460ng ED50) adsorbed on aluminium hydroxide. Description: Suspension for injection. Presentation: Price on request. Indication: Active immunisation for adults against Japanese encephalitis. Pharmacology: The mechanism of […]
Myfenex
February 1, 2011 by Leave a Comment
Company: Teva Pharmaceuticals Ireland. Legal category: Prescription. High Tech. Sport permitted. Active ingredient: Mycophenolate mofetil 250mg, 500mg. Description: 250mg: Hard capsules with blue cap marked M and caramel body marked 250. 500mg: Pale purple, oval shaped film-coated tablets marked M500 on one side. Presentations: 250mg-100, €89.86; 500mg-50, €89.86. Indication: In combination with ciclosporin and corticosteroids […]
Loading ...
